glp-1 drug delivery devices Scientists rethink to improve dosing, tolerability, and adherence Liposomal Semaglutide Could Be the

it's about increasing treatment options and personalizing it to each patient's preferences and needs

Tirzepatides Dual GIP and GLP-1 Action Tirzepatide works through both GLP-1 and GIP pathways

Glucagon-like peptide-1 (GLP-1) receptor agonists aka the -tides, GLP analogs, incretin mimetics *The FDA has approved the use of -glutides to reduce the risk of major cardiovascular events (myocardial infarction, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors

This combination of mechanisms makes Mounjaro more effective at promoting weight loss compared to medications that target just one of these pathways

GLP-1 Receptor agonist was proved by the Action Control Cardiovascular Risk in Diabetes trial (ACCORD) 75% decrease death rate in patients under Exentide treatment

This is Philip Pape, and you've been listening to the Wits and Weights podcast